|
THURSDAY 4 DECEMBER 2008 |
| 07.30 |
Registration opens |
| 08.30 |
Welcome and introduction
C Griffiths (Manchester, UK)
J Barker (London, UK) |
| |
|
GENETICS
Chairs: E. Christophers (Germany), J. Voorhees (USA) |
| 08.45 09:15 |
Invited Lecture
Pathogenetic mechanisms revealed through genome-wide association studies
Prof G Abecasis (Ann Arbor, USA) |
| 09:15 09:30 |
Characterization of ZNF313/RNF114 as a novel psoriasis susceptibility gene
F. Capon , M.-J. Bijlmakers, M. Quaranta, K. Timms, A.D. Burden, A. Reis, R.B. Warren,
C.E.M. Griffiths, J. Worthington, F.O. Nestle, J. Lanchbury, J.N. Barker and R.C. Trembath |
| 09:30 09:45 |
Replication of association of ZNF313/RNF114 locus on chromosome 20q13 with psoriasis
R. Nair , P. Stuart, T. Tejasvi, E. Christophers, J. Voorhees and J. Elder |
| 09:45 10:00 |
Genome-wide scan reveals association of psoriasis with interleukin-23, Th2 and NF-YB pathways
R. Nair, K.C. Duffin, C. Helms, J. Ding, P. Stuart, D. Goldgar, J. Gudjonsson, T. Tejasvi, D. Gladman,
P. Rahman, M. Weichenthal, A. Ruether, J. Fischer, G.M. Lathrop, J.J. Voorhees,
A.B. Begovich, G.G. Krueger, A.M. Bowcock, G.R. Abecasis and J.T. Elder |
| 10.00 10.30 |
Coffee break |
| 10:30 11:00 |
Invited Lecture
The contribution of genomic copy number variation to common human disease
Dr M Hurles (Cambridge, UK) |
| 11:00 11:15 |
Psoriasis is associated with copy number variation of genes involved in innate immunity and
skin barrier function: evidence for genetic interaction with HLA-Cw6
J. Schalkwijk , P.L.J.M. Zeeuwen, D. Rodijk-Olthuis, E.J. Hollox, X. Estivill and J.A.L. Armour |
| 11:15 11:30 |
Preliminary pharmacogenetic assessment of tumour necrosis factor (TNF)
polymorphisms in psoriasis: response to anti-TNF and systemic therapies
T. Tejasvi , P. Stuart, R. Nair, J. Voorhees and J. Elder |
| 11:30 11:45 |
PRINS, the psoriasis susceptibility related noncoding gene RNA interacts with chaperone molecules
and regulates the gene expression of G1P3/IFI6, an antiapoptotic, interferon-inducible protein
M. Szell , K. Szegedi, M. Antal, I. Nemet, E. Sonkoly, Z. Bata-Csorgo, A. Dobozy and L. Kemeny |
| 11:45 12:00 |
HLA-Cw6 allele confers sensitivity to efalizumab treatment in psoriasis
A. Costanzo , M. Talamonti, E. Botti, G. Spallone, M. Papoutsaki and S. Chimenti |
| 12:00 12:45 |
Keynote lecture
Understanding Psoriasis by Genotype and Phenotype Associations
Prof G Krueger (Salt Lake City, USA) |
| 12.45 13.45 |
Lunch and poster viewing |
| |
|
CO-MORBIDITIES AND OUTCOME MEASURES
Chairs: K. Kragballe (Denmark), A. Menter (USA) |
| 13.45 14.15 |
Invited Lecture
Mechanisms of cardio-vascular disease in autoimmunity
Prof I McInnes (Glasgow, UK) |
| 14.15 14.30 |
Comorbidities, healthcare utilization and genetics of psoriasis in a founder population
W. Gulliver , N. Gladney, D. MacDonald, K.D. Collins and R. Alaghehbandan |
| 14:30 14:45 |
A new tool assessing quality of life in patients with psoriasis: the QualiPSo questionnaire
B. Quintard , A. Constant, M.L. Bouyssou-Gauthier, C. Paul, F. Truchetet, P. Thomas, Y. Guiguen and A. Taeib |
| 14:45 15:00 |
Evaluation of a novel three-dimensional Psoriasis Severity Index (PSI) by comparison with the
Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI): a pilot study
R.J.G. Chalmers , C.E.M. Griffiths and R.B. Warren |
| 15:00 15:15 |
Clinical predictors for psoriatic arthritis in patients with psoriasis
V. Chandran, S.M.A. Toloza, S. Shanmugarajah, F.J. Pellett,
C.T. Schentag, C.T. Rosen and D.D. Gladman |
| 15.15 15.45 |
Invited Lecture
Registries for biologics - what can they teach us?
Prof D Symmons (Manchester, UK) |
| 15:45 16:00 |
Tea |
| 16.00 17.00 |
Integrated Symposium
Interactive Debate: Psoriasis is a Progressive Disease
Chair: Christopher Griffiths (United Kingdom)
FOR: CV co-morbidities are progressive and life-threatening - Wolf-Henning Boehncke (Germany)
AGAINST: Skin pathology contributing to complete healing - Mona Stahle, (Sweden)
FOR: Quality of life impact is progressively damaging to patients - Alexa Kimball (USA)
AGAINST: Optimising disease management to clear the skin - Alan Menter (USA)
Questions from the floor
Summary and Audience Vote
Symposium sponsored by Abbott |
| 17.15 18.15 |
Integrated Symposium
Pharmacogenetics and Response to Efalizumab
Chair: David Burden (United Kingdom)
Introduction D. Burden (UK)
HLA Cw6 & response to Efalizumab W. Gulliver (Canada)
CONTROL II (IMP25300) Pharmacogenetics & Efalizumab G. Stingl (Austria)
Questions and panel discussion
Symposium sponsored by Merck Serono |
| 18.15 |
Close of Congress sessions |
| 18.15 19.30 |
Welcome Reception
Royal College of Physicians |
| |
|
|
Friday 5th December 2008
IMMUNOLOGY AND IMMUNITY
Chairs: F. Nestle (UK), J. Prinz (Germany) |
| 08.15 09:15 |
Integrated Symposium
New Views on Nail Anatomy and Psoriasis
Chair: Professor J-H. Saurat (Switzerland)
Psoriasis and Systemic Inflammation: Underdiagnosed Enthesopathy G. Girolomoni (Italy)
The Nail as a Skeletal Appendage-Implications for Understanding the Link Between Psoriasis and Arthritis - D. McGonagle (UK)
Approach to Managing Patients With Nail Involvement K. Reich (Germany)
Questions and Answers
Symposium sponsored by Schering Plough |
| 09:30 10:00 |
Invited Lecture
The IL-23/TH17 axis in Autoimmunity
Dr R Kastelein (Palo Alt, USA) |
| 10:00 10:30 |
Coffee break |
| 10:30 10:45 |
The cytokine pattern of lesional psoriatic T-cell clones: dominance of Th17 cells
S. Vollmer, P. Besgen, S-M. Kim and J.C. Prinz |
| 10:45 11:00 |
Phenotype and functional confirmation that Th17 cells constitute the major CD4 population
in psoriatic lesions and are likely to have a major pathogenic role
B.J. Lewis , A.D. Ormerod and R.N. Barker |
| 11:00 11:30 |
Invited Lecture
The innate immune response and psoriasis
Prof B Nickoloff (Chicago, USA) |
| 11:30 11:45 |
The role of T cells in psoriasis
U. Laggner , C. Hundhausen, G. Perera, E. Botti, R. Mak, A. Hayday and F.O. Nestle |
| 11:45 12:00 |
Induction of interleukin-17+ T-cell trafficking and development by interferon Y: mechanism and pathological relevance in psoriasis
A. Bruce , I. Kryczek, J. Gudjonsson, A. Johnston, A. Aphale, L. Vatan, W. Szeliga, Y. Wang, Y. Liu, T. Welling, J. Elder and W. Zou |
| 12:00 13:25 |
Lunch and poster viewing |
| 13:25 14:10 |
Keynote lecture
Translating advances in understanding psoriasis immunology in to new therapies
Prof G Stingl (Vienna, Austria) |
| 14.10 14.25 |
Development and validation of human psoriatic skin equivalents
G. Tjabringa , M. Bergers, R. de Boer, M. Erkens, H. Koenen, I. Joosten and J. Schalkwijk |
| 14:25 14:40 |
Induced expression of vanins in lesional psoriatic skin: regulation by proinflammatory cytokines
P. Jansen , P. Zeeuwen and J. Schalkwijk |
| 14:40 15:40 |
Integrated Symposium
Integrated SymposiumTranslational Research Into the Therapeutic Role of Targeting IL-12/IL-23- From Bench to Bedside
Scientific Committee and Co-Chairs: Professor Christopher Griffiths (UK) and Professor Jim Krueger (USA)
Introduction: Development of innovative biologic therapies, driven by a betterunderstanding of the pathophysiology of psoriasis - Professor Christopher Griffiths (UK)
Clinical implications of genetic discoveries in psoriasis - Professor Jonathan Barker (UK)
Inherited disorders of human IL12B and IL12RB1: clinical and immunological
Implications - Professor Jean-Laurent Casanova (France)
Effect of ustekinumab on resident and inflammatory leukocyte populations - Professor Jim Krueger (USA)
Discussion / Q&A Moderated by Chairmen
Symposium sponsored by Janssen-Cilag |
| 15.45 16.15 |
Tea |
| 16.15 17.15 |
Integrated Symposium
Joint management: interdisciplinary approach to psoriatic arthritis
Chair: Professor W. Sterry (Germany)
Optimal management of psoriasis patients with psoriatic arthritis - O. FitzGerald (Ireland)
Recent clinical developments in treating psoriasis patients with psoriatic arthritis W. Sterry (Germany)
Psoriatic arthritis: disease impact on patient quality of life K. Reich (Germany)
Summary & Close W. Sterry (Germany)
Symposium sponsored by Wyeth |
| 17:15 |
Close of Congress sessions |
| 19:30 |
Congress Banquet
Stationers Hall |
| |
|
Saturday 6th December 2008
TARGETED THERAPEUTICS
Chairs: A. Giannetti (Italy), J. Saurat (Switzerland) |
| 09.00 09.15 |
Adalimumab therapy rapidly inhibits p38 mitogen-activated protein kinase activity in lesional psoriatic skin preceding clinical improvement
L.S. Madsen, C. Johansen, L. Iversen and K. Kragballe |
| 09:15 09:30 |
Preferential inhibition of interleukin (IL)-17C, IL-1Y and p38 mitogen-activated
protein kinase in psoriatic skin by antitumour necrosis factor-Y therapy
C. Johansen , L. Soegaard, L. Iversen and K. Kragballe |
| 09:30 09:45 |
Activation of PPAR delta causes a psoriasis- like skin disease in vivo
M. Romanowska , S. Niteshwaran, C. Palmer and J. Foerster |
| 09:45 10:00 |
Th17/Treg paradigm: effect of 8-methoxypsoralen plus ultraviolet A in a mouse model of psoriasis
T.P. Singh , M.P. Schφn, K. Michaelis, X-J. Wang, H. Kerl and P. Wolf |
| 10.00 10:30 |
Invited Lecture
Making drugs out of biology
Prof F Walsh (Collegeville, USA) |
| 10:30 11:00 |
Coffee Break |
| 11:00 11:30 |
Invited Lecture
Health economic and social implications of psoriasis and its management
Prof M Augustin (Hamburg, Germany) |
| 11:30 11:45 |
Alleviation of psoriasis upon genetic knockdown of human tumour necrosis factor-α by lentivirus-encoded short hairpin RNA in a xenograft transplantation model
K. Stenderup, M. Jacobsen, C. Rosada, B. Moldt, S. Kamp, T.N. Dam, T.G. Jensen and J.G. Mikkelsen |
| 11:45 12:00 |
Identification of genetic risk markers of efalizumab response
G. Stingl , E. Monnet and A. Constanzo |
| 12:00 12:45 |
Keynote lecture
Rationing therapeutic interventions in the 21st century
Prof Sir M Rawlins (London, UK) |
| 12.45 |
Presentation of poster prizes and close of Congress
Prof J Barker (London, UK)
Prof C Griffiths (Manchester, UK) |
